Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAnesthesiologyCurative Malignant Hyperthermia Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentCurativePolicy CHP-IP-2026-163

    Malignant Hyperthermia

    Customize your policy alerts

    Sign up for curative Policy CHP-IP-2026-163 alerts

    Get alerted when Policy CHP-IP-2026-163 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity for inpatient admission, observation, ICU, step-down, medical-surgical care, continued stay, and discharge after suspected or confirmed malignant hyperthermia triggered by volatile anesthetics or succinylcholine for Curative commercial members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerCurative
    PolicyMalignant Hyperthermia
    Policy CodePolicy CHP-IP-2026-163
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the anesthetic agents administered, the timing of the first sign, and the sequence of clinical findings.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All agesApplicable population
    24 hoursMinimum ICU monitoring
    24–48 hoursTypical monitoring benchmark
    DailyConcurrent review
    ~1 in 5Recrudescence rate

    Medical Necessity and Level-of-Care Criteria

    Acute inpatient admission

    Acute inpatient admission, including conversion from outpatient or ambulatory surgery, is medically necessary after a suspected MH event when all of the following are met.

    Inpatient admission

    • At least one clinical severity finding

      • Severity findings: End-tidal CO2 above 55 mm Hg or PaCO2 above 60 mm Hg despite appropriately controlled ventilation; generalized muscle rigidity or masseter rigidity followed by other hypermetabolic signs; arterial pH below 7.25 or base deficit greater than 8 mmol/L; potassium above 6.0 mmol/L, ventricular arrhythmia, or unexplained sinus tachycardia; rapidly rising temperature or temperature above 38.8°C in the perioperative period; CK above 10,000 U/L, CK above 20,000 U/L after succinylcholine, cola-colored urine, or myoglobinuria; or dantrolene administered for suspected MH.
    • At least one hospital-level service required

      • Hospital-level services: Continuous monitoring in an ICU or equivalent post-anesthesia critical care area for at least 24 hours after the episode; maintenance intravenous dantrolene with serial assessment for recrudescence; serial arterial blood gases, potassium, CK, creatinine, coagulation studies, and urine myoglobin; or active cooling, treatment of hyperkalemia or arrhythmia, forced diuresis for myoglobinuria, or mechanical ventilation.

    Observation or outpatient instead of inpatient

    Observation or outpatient management is appropriate when any of the following applies and no inpatient severity finding is present.

    Observation or outpatient management

    • Applicable lower-acuity scenario: Isolated masseter muscle rigidity after succinylcholine resolved without hypercarbia, acidosis, hyperkalemia, or temperature rise; use extended monitoring, commonly at least 12 hours, with CK and urine myoglobin, and admit only if abnormal findings develop.
    • Applicable lower-acuity scenario: Known or suspected MH susceptibility with an uneventful non-triggering anesthetic; use standard post-anesthesia recovery and discharge.
    • Applicable lower-acuity scenario: Isolated mild end-tidal CO2 rise corrected by ventilator adjustment, with no other signs and no dantrolene; use post-anesthesia observation.

    Intensive care unit

    ICU placement is appropriate when any of the following is present.

    ICU level of care

    • Any MH crisis treated with dantrolene, for at least the first 24 hours after control.
    • Recrudescence requiring repeat dantrolene boluses.
    • Mechanical ventilation, vasopressor requirement, ventricular arrhythmia, or potassium 6.5 mmol/L or higher.
    • Acute kidney injury from myoglobinuria requiring renal replacement therapy, or disseminated intravascular coagulation.

    Step-down or intermediate care

    Step-down or intermediate care is appropriate when any of the following is present and no ICU criterion is met.

    • More than 24 hours after control, with dantrolene stopped or being weaned and a need for continued cardiac monitoring.
    • CK remains above 10,000 U/L or myoglobinuria persists with hourly urine-output monitoring.

    Medical-surgical unit

    Medical-surgical placement is appropriate when any of the following describes the patient and no higher-level criterion is met.

    Medical-surgical level of care

    • Temperature, end-tidal or arterial CO2, potassium, and pH are stable for at least 24 hours, with CK falling.
    • Postoperative care needs from the original surgery are the main reason for continued stay.

    Discharge readiness

    Discharge from acute inpatient care is appropriate when all of the following are met.

    • No hypermetabolic signs—temperature below 38.0°C, normal potassium and pH, and no rigidity—for at least 24 hours after the last dantrolene dose.
    • CK is falling, urine is clear of myoglobin, and creatinine is at or near baseline.
    • Postoperative discharge criteria for the index surgery are met.
    • The patient and family have been informed of MH susceptibility; referral for susceptibility testing, including genetic testing and/or contracture testing, and medical-alert identification are documented; and the event is reported to a national MH registry as recommended.

    Continued acute inpatient stay

    Continued acute inpatient stay is medically necessary at daily concurrent review when any of the following is documented.

    Continued-stay criteria

    • Fewer than 24 hours of stability after the last dantrolene dose, or recrudescence.
    • Rhabdomyolysis with CK not yet falling, myoglobinuria, or acute kidney injury.
    • A complication requiring acute treatment, including compartment syndrome, coagulopathy, pulmonary edema, or arrhythmia.
    • Postoperative needs from the index surgery that independently meet the surgical policy's continued-stay criteria.

    This policy addresses inpatient admission, observation, and level-of-care management after a suspected or confirmed malignant hyperthermia crisis triggered by a volatile anesthetic or succinylcholine, including conversion of a planned outpatient or ambulatory surgery procedure to inpatient care. Neuroleptic malignant syndrome, serotonin syndrome, and heat stroke are outside the scope of this policy. The surgical admission itself is reviewed under the applicable procedure policy.

    Admission solely because a patient is susceptible to malignant hyperthermia is not medically necessary at the inpatient level when a non-triggering anesthetic is planned and the procedure is otherwise appropriate for outpatient care. MH susceptibility alone does not require inpatient admission; the request is referred for physician review when applicable.

    When masseter rigidity is isolated and resolves without hypercarbia, acidosis, hyperkalemia, or temperature rise, and extended monitoring shows normal CK, potassium, and blood gases, acute inpatient care is not medically necessary. Observation, with outpatient disposition when clinically appropriate, is the expected level of care; extended monitoring commonly lasts at least 12 hours with CK and urine-myoglobin assessment.

    Continued acute inpatient days solely while awaiting placement in skilled nursing, rehabilitation, long-term acute care, behavioral health, or home services are not covered after discharge-readiness criteria are met and no acute hospital-level service remains. Active discharge planning is required; days already authorized are not retroactively denied.

    Custodial care, family or provider convenience, and non-urgent tests or consultations do not support acute inpatient coverage when the service could safely be provided at a lower level of care or after discharge. These requests are referred for physician review when applicable.

    Coding and Clinical Thresholds

    ICD-10-CMICD-10
    T88.3XXAMalignant hyperthermia due to anesthesia, initial encounter
    M62.82Rhabdomyolysis
    MS-DRG (FY 2027 v44) when MH is principalRevenue
    919MS-DRG 919
    920MS-DRG 920
    921MS-DRG 921
    Revenue codesRevenue
    0200Revenue code 0200
    0206Revenue code 0206
    0250Revenue code 0250
    0300Revenue code 0300
    0762Revenue code 0762
    End-tidal CO2 or PaCO2
    End-tidal CO2 thresholdAbove 55 mm Hg despite appropriately controlled ventilation
    PaCO2 thresholdAbove 60 mm Hg despite appropriately controlled ventilation
    Clinical significanceEither finding is a clinical severity finding supporting acute inpatient admission after a suspected MH event
    Acid-base severity
    Arterial pHBelow 7.25
    Base deficitGreater than 8 mmol/L

    Documentation, Review, and Determination Requirements

    Documentation Required

    Document Triggering Agents and Event Chronology

    Include the anesthetic agents administered, the timing of the first sign, and the sequence of clinical findings during the suspected malignant-hyperthermia event.

    • Document end-tidal CO2, heart rate, rigidity, and temperature in chronological order.
    Documentation Required

    Provide Serial Laboratory Monitoring

    Provide serial laboratory results to demonstrate the clinical course and response to treatment.

    • Include arterial blood gases, potassium, CK, myoglobin, creatinine, and coagulation results over time.
    Documentation Required

    Document Dantrolene Treatment

    Document the complete dantrolene treatment record, including the total dose administered and the ongoing treatment plan.

    Clinical Context

    Malignant hyperthermia is a pharmacogenetic skeletal-muscle disorder commonly associated with variants in RYR1 or CACNA1S. Exposure to volatile anesthetics or succinylcholine can cause uncontrolled calcium release, leading to hypermetabolism, rigidity, hyperthermia, acidosis, hyperkalemia, and rhabdomyolysis. Early findings may include an unexplained rise in end-tidal CO2, tachycardia, and rigidity, while hyperthermia may occur later. Treatment includes stopping triggering agents, high-flow oxygen and hyperventilation, repeated dantrolene, cooling, and correction of metabolic complications. Because recrudescence may occur after initial control, ICU-level monitoring is supported for at least 24 hours.

    Policy Definitions and Planning Benchmarks

    MH crisis
    Triggering exposureDuring or soon after exposure to a volatile anesthetic or succinylcholine
    Hypermetabolic findingsAny unexplained end-tidal CO2 rise, generalized rigidity, rapidly rising temperature, metabolic or respiratory acidosis, hyperkalemia, or myoglobinuria
    TreatmentTreated with dantrolene
    Recrudescence
    DefinitionReturn of hypermetabolic signs after initial control
    Typical timingMost often within the first 24 hours
    Required response
    Policy Summary
    PayerCurative
    PolicyMalignant Hyperthermia
    Policy CodePolicy CHP-IP-2026-163
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the anesthetic agents administered, the timing of the first sign, and the sequence of clinical findings.
    SourceLink
    On This Page
    Medical Necessity and Level-of-Care CriteriaCoding and Clinical ThresholdsDocumentation, Review, and Determination RequirementsClinical ContextPolicy Definitions and Planning Benchmarks
    Clinical significance
    Either finding is a clinical severity finding supporting acute inpatient admission after a suspected MH event
    Potassium and temperature
    PotassiumAbove 6.0 mmol/L
    TemperatureAbove 38.8°C in the perioperative period
    Clinical significanceEither finding is an MH severity finding; potassium above 6.0 mmol/L is also listed with ventricular arrhythmia or unexplained sinus tachycardia
    Creatine kinase
    General CK thresholdAbove 10,000 U/L
    Post-succinylcholine CK thresholdAbove 20,000 U/L after succinylcholine
    Associated findingsCola-colored urine or myoglobinuria also support an acute MH severity finding
    Critical potassium threshold
    Potassium threshold6.5 mmol/L or higher
    Electrocardiographic findingHyperkalemic ECG changes
    Required responseImmediate treatment of hyperkalemia and ICU care
    Monitoring and stability duration
    Initial ICU monitoringAt least 24 hours after the episode or after control of an MH crisis treated with dantrolene
    Discharge stabilityAt least 24 hours without hypermetabolic signs after the last dantrolene dose
    Discharge findingsTemperature below 38.0°C, normal potassium and pH, no rigidity, falling CK, clear urine without myoglobin, and creatinine at or near baseline
    Recrudescence concernReturn of end-tidal CO2 rise, tachycardia, rigidity, or temperature rise requires repeat dantrolene and continued or resumed ICU care
    • Record the total dantrolene dose.
    • Document the maintenance regimen.
    • Record the timing of the last dose.
    Documentation Required

    Include Clinical Grading

    Include the Larach clinical grading scale score when available to support the assessment of malignant-hyperthermia likelihood.

    Documentation Required

    Support Concurrent Review and Discharge Planning

    For each concurrent-review period, document assessment for recrudescence, the rationale for the current level of care, and discharge planning. Include discharge counseling and referral for malignant-hyperthermia susceptibility testing when appropriate.

    • Concurrent review applies to each continued-stay period.
    • Days already authorized are not retroactively denied.
    • An expected length of stay is a planning benchmark, not a limit on covered days.
    • Document active discharge planning and the level-of-care rationale at each review.
    Denial Risk

    Support the Requested Extent of Service

    The requested extent of service must be supported by the clinical documentation. Requested quantity, units, or duration that exceed the supported amount may be reviewed separately.

    • Document the quantity, units, and duration requested.
    • When applicable, approve the supported portion and separately address only the unsupported increment.
    Denial Risk

    Scenarios Not Meeting Inpatient Criteria

    Requests that do not meet the applicable inpatient medical-necessity criteria are referred for physician review and are not denied by an automated system or non-physician reviewer.

    • Admission solely because a patient is MH-susceptible does not meet inpatient criteria when a non-triggering anesthetic is planned and the procedure is otherwise appropriate for outpatient care.
    • Isolated, resolved masseter rigidity with normal CK, potassium, and blood gases after extended monitoring is appropriate for observation rather than acute inpatient care.
    • Continued inpatient days solely while awaiting placement after discharge readiness, without acute hospital-level services, do not meet acute inpatient criteria; pursue active discharge planning.
    • Days used for custodial care, family or provider convenience, or scheduling non-urgent services that can safely occur at a lower level of care or after discharge do not meet acute inpatient criteria.
    Note

    Physician Review Required for Adverse Determinations

    Only a licensed physician of the same or similar specialty may issue an adverse determination, and the requesting provider must be offered a peer-to-peer discussion.

    • Automated systems and non-physician clinical reviewers may approve a request in full or in part but may not issue an adverse determination.
    • The reviewing physician must satisfy applicable licensure, specialty, and medical-director requirements of the plan's situs state.
    Billing Rule

    Address Unsupported Quantity or Duration

    When the requested quantity, units, or duration exceed what the documentation supports, approve the supported portion when applicable and separately review only the unsupported increment.

    • Do not treat an unsupported increment as grounds to deny the entire supported service.
    • Requests that fail criteria must be referred to a qualified physician reviewer.
    Treat as recrudescence with repeat dantrolene and keep or return the patient to ICU
    Expected length of stay
    PurposePlanning benchmark for an uncomplicated course
    Coverage limitationNot a limit on covered days
    Continued-stay reviewContinued inpatient stay is reviewed for documented medical necessity during each continued-stay period